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Abstract
Background: Endothelial dysfunction has been proposed as the underlying cause of diabetic angiopathy that
eventually leads to cardiovascular disease, the major cause of death in diabetes. We recently demonstrated the
ameliorating effect of regular vitamin D intake on the glycemic status of patients with type 2 diabetes (T2D). In this
study, the effects of improvement of vitamin D status on glycemic status, lipid profile and endothelial biomarkers
in T2D subjects were investigated.
Methods: Subjects with T2D were randomly allocated to one of the two groups to receive either plain yogurt
drink (PYD; containing 170 mg calcium and no vitamin D/250 mL, n1 = 50) or vitamin D3-fortified yogurt drink
(FYD; containing 170 mg calcium and 500 IU/250 mL, n2 = 50) twice a day for 12 weeks. Anthropometric
measures, glycemic status, lipid profile, body fat mass (FM) and endothelial biomarkers including serum endothelin-
1, E-selectin and matrix metalloproteinase (MMP)-9 were evaluated at the beginning and after the 12-week
intervention period.
Results: The intervention resulted in a significant improvement in fasting glucose, the Quantitative Insulin Check
Index (QUICKI), glycated hemoglobin (HbA1c), triacylglycerols, high-density lipoprotein cholesterol (HDL-C),
endothelin-1, E-selectin and MMP-9 in FYD compared to PYD (P < 0.05, for all). Interestingly, difference in changes
of endothelin-1, E-selectin and MMP-9 concentrations in FYD compared to PYD (-0.35 ± 0.63 versus -0.03 ± 0.55, P
= 0.028; -3.8 ± 7.3 versus 0.95 ± 8.3, P = 0.003 and -2.3 ± 3.7 versus 0.44 ± 7.1 ng/mL, respectively, P < 0.05 for all),
even after controlling for changes of QUICKI, FM and waist circumference, remained significant for endothelin-1
and MMP-9 (P = 0.009 and P = 0.005, respectively) but disappeared for E-selectin (P = 0.092). On the contrary, after
controlling for serum 25(OH)D, the differences disappeared for endothelin-1(P = 0.066) and MMP-9 (P = 0.277) but
still remained significant for E-selectin (P = 0.011).
Conclusions: Ameliorated vitamin D status was accompanied by improved glycemic status, lipid profile and
endothelial biomarkers in T2D subjects. Our findings suggest both direct and indirect ameliorating effects of
vitamin D on the endothelial biomarkers.
Trial registration: ClinicalTrials.gov: NCT01236846
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The prevalence of type 2 diabetes (T2D) is increasing
worldwide, including Iran [1]. It has been shown that
diabetes is accompanied by remarkably greater risk for
cardiovascular disease (CVD). Accounting for more than
80% of all premature deaths, CVD has been known as
the major cause of mortality in T2D [2].
Diabetes may affect both small and large vessels, lead-
ing to micro- and macro-angiopathy, respectively.
Hyperinsulinemia and augmented oxidative stress,
usually both present in diabetes, are known as two
major contributing factors of the long-term complica-
tions, including micro- and macro-angiopathy [3]. It is
hypothesized that endothelial dysfunction is the underly-
ing cause of diabetic angiopathy that eventually leads to
C V D[ 4 ] .H o w e v e r ,ap o p u l a t i o n - b a s e ds t u d ys h o w e d
that raised plasma concentrations of endothelial biomar-
kers may predict diabetes independent of such diabetes
risk factors as obesity, insulin resistance and systemic
inflammation [5]. The endothelial function may there-
fore be the focus of preventive efforts against both dia-
betes and its fatal complications.
The relationship between vitamin D and T2D has
recently been the focus of interest. Vitamin D, mostly
known for its calcemic functions, has been shown to
have many non-calcemic actions including regulation of
gene expression and antioxidant properties [6]. Vitamin
D deficiency has been proposed as an independent risk
factor for CVD [7]. It has been recently reported that the
odds ratio for having CVD outcomes in individuals with
serum 25(OH)D below 25 nmol/L, compared to those
with 25(OH)D ≥37.5 nmol/L, after adjustment for poten-
tial confounders was 2.90 (95% confidence interval: 1.67
to 5.12, P < 0.001) [8]. Considering the role of endothelial
dysfunction in development of CVD, the issue has been
raised if vitamin D can influence the endothelia. Vitamin
D deficiency has been associated with endothelial dys-
function and lipid peroxidation in non-diabetic adults
[9]. We have recently shown in another study on a sepa-
rate population that vitamin D intake in subjects with
T2D improves glycemic control [10]. In the current
study, it was hypothesized that the effect of improvement
of vitamin D status via daily intake of a vitamin D3-forti-
fied Persian yogurt drink (doogh) can affect endothelial
biomarkers independent of glycemic status.
Methods
Sample size
Based on our previous data on the mean serum 25(OH)
D in Iranian diabetic patients (57.8 ± 47.8 nmol/L) [11],
to detect a change in mean 25(OH)D of 1 standard
deviation (SD; effect size of 1) and to have a power of
90%, the calculated sample size was 50 in each group.
Subjects
A total of 100 known patients with T2D (57 women and
43 men) 52.5 ± 7.4 years old (range 29 to 67 years) were
randomly selected from our original study population
[12], all recruited from the Iranian Diabetes Society or
Gabric Diabetes Society, both located in Tehran. The
inclusion criteria were: (a) age 25 to 70 years old, (b)
willingness to participate, and (c) no use of vitamin,
dietary, herbal or omega-3 supplements for at least 3
months prior to the intervention period. Exclusion cri-
teria included: (a) history of cardiovascular, gastrointest-
inal, renal, and other endocrinological diseases, (b)
pregnancy or lactation, (c) receiving insulin, and (d)
treatment for weight reduction. All subjects were already
receiving oral hypoglycemic medications including met-
fromin, glibenclamide and glitazone. There was no sta-
tistical difference between the two groups in distribution
of each drug usage (data not shown).
Study protocol
Figure 1 shows the study protocol. The study was a part
of a bigger research project on the evaluation of the
effect of vitamin D receptor variants on response to
vitamin D intake [12]. This was a 3-month randomized
controlled clinical trial (RCT) bicentrally conducted dur-
ing mid-October 2010 to late March 2011 by the
National Nutrition and Food Technology Research Insti-
tute (NNFTRI) and School of Public Health of Tehran
University of Medical Sciences (TUMS). On the first
visit, the study protocol and objectives were fully
explained to all participants before they were given an
informed written consent to sign. After a 2-week run-in
period, participants were randomly allocated to either
vitamin D3-fortified doogh (FYD; containing 170 mg
calcium and 500 IU vitamin D3/250 mL; n1 = 50) or
plain doogh (PYD; containing 170 mg calcium and no
detectable vitamin D/250 mL; n2 = 50). Protein, fat and
energy contents of dooghs were 1.4 g/dL, 1.0 g/dL and
30 kcal/dL, respectively. Participants were instructed to
consume a bottle of doogh with both lunch and dinner,
that is 500 mL/day equaling 1000 IU vitamin D3 a day
in FYD group. The intervention period was 12 weeks.
Consumption of 1000 IU/day vitamin D is believed to
be a safe and effective way to increase circulating 25
(OH)D in this study period [10]. Participants were given
dooghs in 30-bottle packs, which were enough for 2
weeks. All subjects were visited biweekly both to assess
their compliance and to provide them with dooghs for
the next two weeks. Blood pressure, anthropometric,
dietary, body fat and laboratory evaluations were pre-
formed both before and after the intervention. Both par-
ticipants and examiners were unaware of the group
allocations. The primary outcome was considered a
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The study protocol was approved scientifically and ethi-
cally by appropriate committees of NNFTRI, Shahid
Beheshti University of Medical Science, and TUMS.
Assessment of dietary intake
Dietary intake was assessed using a 24-hour recall ques-
tionnaire for 3 days (including a weekend) at the begin-
ning and in the end of the intervention period. All the
questionnaires were completed with the aid of a trained
dietitian. A food album was used to help the partici-
pants to recall the portion sizes of the foods consumed,
which were then converted to grams using household
measures. Data on energy and nutrient intakes were
d e r i v e df r o mf o o di n t a k eq u e s t i o n n a i r e su s i n gU S
Department of Agriculture (USDA) food composition
tables with some modifications for Iranian foods.
Anthropometrics and blood pressure
Weight was measured with light clothes and without
shoes using a digital scale (Seca 808, Hamburg, Ger-
many) to the nearest of 0.1 kg. Height was measured
without shoes using a stadiometer (Seca, Hamburg, Ger-
many) to the nearest of 0.1 cm. Circumferences of the
 
 
 12 Weeks Follow Up  
Run-in period (2 weeks)  
Baseline measurements 
Dietary, anthropometry, BP, Lab 
assessments  
Fortified doogh     
(FYD), n2=50 
Random allocation  
Plain doogh         
(PYD), n1=50 
Final measurements 
Dietary, anthropometry, BP, 
Laboratory assessments 
Data analysis  
Subjects with type 2 
diabetes (N=100) 
Figure 1 The study protocol at a glance.
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nearest of 0.1 cm. Body massi n d e x( B M I )w a sc a l c u -
lated using the equation BMI = weight (kg)/height
2 (m).
To measure blood pressure (BP), subjects remained in a
sitting position for at least 10 minutes. BP was then
measured twice by a digital sphygmomanometer (BC08,
Beurer, Germany). The average of the two measure-
ments was considered as the BP of the patient.
Laboratory investigations
Blood sampling and handling
A blood sample was drawn between 07.00 and 10.00
AM after 12 hours of fasting. Blood samples were cen-
trifuged within 30-45 minutes of collection, and sera
were transferred to clean micro-tubes in aliquots, which
were kept frozen at -80°C until analysis.
Glycemic status, lipid profile and urinary albumin
Fasting serum glucose (FSG), lipid profile including tria-
cylglycerols (TG), total cholesterol (TC), low-density
lipoprotein cholesterol (LDL-C), and HDL-C were deter-
mined using enzymatic methods. Urinary albumin and
creatinine were measured by immunoturbidometric and
colorometic methods, respectively. All these tests were
done by commercial kits (all from Pars Azmoon, Teh-
ran, Iran) using an auto-analyzer system (Selectra E,
Vitalab, Holliston, the Netherlands). As albumin was
measured in spot urine samples, urinary albumin to
creatinine ratio (ACR) was used to evaluate changes in
microalbuminuria. HbA1c was determined using a col-
orometric method after an initial chromatographic
separation (BioSystems, Barcelona, Spain). Serum insulin
levels were measured by immunoradiometric assay
(IRMA) using a commercial kit (Biosource, Dorest, Bel-
gium) and a g-counter system (Gamma I, Genesys,
Maple Park, USA). Insulin resistance was evaluated by
QUICKI calculated as [13]:
QUICKI index : 1/[log (insulin)( µU/mL) +l o g(glucose)(mg/dL)]
Circulating 25(OH)D3
Serum 25(OH)D3 concentrations were measured by a high
performance liquid chromatography (HPLC) method as
described elsewhere [14]. The intra- and inter-assay varia-
tions were less than 7% and 9%, respectively. Vitamin D
status was defined based on serum concentrations of 25
(OH)D as: sufficient ≥50 nmol/L; 27.5 nmol/L ≤ insuffi-
ciency < 50 nmol/L; and deficiency < 27.5 nmol/L [15]. It
has been recently shown that the vitamin D requirements
of at least 97.5% of the population can be met with circu-
lating 25(OH)D concentrations of 50 nmol/L [16]. Serum
intact parathyroid hormone (iPTH) (DRG, Marburg, Ger-
many) concentration was determined using enzyme
immunoassay (EIA). The intra- and inter-assay variations
were less than 3% and 5.5%, respectively.
Endothelial biomarkers
Endothelial function was evaluated by determination of
serum levels of endothelin-1, E-selectin (both from IBL,
Hamburg, Germany) and MMP-9 (e-Bioscience, Vienna,
Austria). All ELISA tests were performed with the aid of
an automatic plate reader (StatFax 3200, Awareness,
Palm City, USA). The intra- and inter-assay variations
were less than 8.1% and 8.5% for endothelin-1, 5.4% and
6.0% for E-selectin, and 7.3% and 10.2% for MMP-9,
respectively.
Body composition analysis
The percentage of body fat was evaluated using bioelec-
trical impedance analysis (Quadscan 4000 system, Body-
stat, Isle of Man, UK).
Compliance
All participants were given a pamphlet on “instructions
to use dooghs” together with a “doogh consumption
table” comprised of 28 empty boxes for each week. Sub-
jects were instructed to mount the table in an exposed
place (preferably on the refrigerator) and to tick each
box after consuming a doogh with each meal. Moreover,
they were asked to bring the empty bottles back on
their next visit. Compliance was evaluated by checking
the consumption tables, counting the empty bottles, and
direct inquiry both on the biweekly visits and weekly
follow-up phone calls.
Quality control of the product
The composition (including vitamin D3) of dooghs was
evaluated immediately after production, in the middle and
at the end of the storage period, to ensure the stability of
the components, especially vitamin D, in the product. The
measurements were done at the Maad Laboratory of
Foods, Drinks and Cosmetics, accredited by the Deputy of
Food and Drug of the Iranian Ministry of Health.
Statistical Analyses
Normal distribution of data was assured using Kolmogrov-
Smirnov. Data were expressed as mean ± SD. Within- and
between-group comparison of data was done using paired
t test and student t test, respectively. To control confound-
ing factors in between-group comparisons, analysis of cov-
ariance (ANCOVA) was employed. Correlations between
t w os e t so fd a t aw e r ed o n eu s i n gt h eP e a r s o ne q u a t i o n .
Categorical variables were compared using chi-square. In
this study, P value < 0.05 was considered significant. All
statistical analyses were done using the statistical package
for social sciences (SPSS) for Windows version 11.5 (SPSS
Inc., Chicago, IL).
Results
General characteristics and dietary intakes
The distribution of age, gender, duration of disease and
consumption of statins did not differ significantly
between the two groups (Table 1). The average intake of
total energy and nutrients (except for vitamin D) also
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ence (data not shown).
Anthropometry, body fat mass and blood pressure
The initial values of anthropometric measures did not
show any significant differences (Table 2). In the FYD
group, compared to the PYD groyp, waist circumference
(WC), BMI and FM all decreased significantly by the
end of the intervention. However, weight changes did
not differ between the two groups. Body FM showed a
small but significant increase in the PYD group (P =
0.019) and an insignificant decrease in the FYD group.
The changes in FM did not differ significantly between
the two groups (Table 3). In the FYD group, final values
of both systolic (SBP) and diastolic blood pressure
(DBP) showed a small but significant decrease compared
to the initial values (P =0 . 0 0 7a n dP =0 . 0 0 2 ,r e s p e c -
tively), but changes of SBP and DBP did not differ sig-
nificantly between the two groups (P =0 . 1 5 0a n dP =
0.090, respectively).
Serum 25(OH)D and vitamin D status
As expected, circulating 25(OH)D was raised in the FYD
group from baseline (P < 0.001) and compared to the PYD
group, the increment was significant (P < 0.001). While
the occurrence of poor vitamin D status (25OHD < 50
nmol/L) did not differ significantly between the two
groups at baseline (74.5% versus 77.6%, c
2 =0 . 0 6 2 ,P =
0.803), the percentage of vitamin D deficiency in the FYD
group significantly dropped to only 4.5%, but in the PYG
group it increased from 31.4% to 48.8% (P < 0.001) (Table
4). The increase in serum 25(OH)D in the FYD group was
accompanied by a significant decrement in iPTH (Table
2). Changes of serum iPTH, however, did not differ signifi-
cantly between the two groups (P = 0.07) (Table 3).
Glycemic status and lipid profile
Generally, the glycemic status (notably FSG, insulin and
Q U I C K I )i nt h eF Y Dg r o u p ,c o m p a r e dt ot h eP Y D
group, improved significantly. To evaluate the possible
effect of the changes of the amount of FM or its
Table 1 Some selected individual characteristics of the
two groups
Variable PYD (n = 50) FYD (n = 50) P value
Age (years) 52.4 ± 8.4 52.6 ± 6.3 0.86
Sex (male/female) 19/31 24/26 0.28
Post-menopausal females 18/19 22/24 0.40
Diabetes duration 7 ± 5.2 8.3 ± 4.6 0.18
Smoking no. (%) 1 (2) 5 (10) 0.18
Using statin no. (%) 4 (3.9) 5 (4.9) 0.75
Data presented as mean ± standard deviation or percentage unless stated
otherwise
FYD: vitamin D-fortified doogh; PYD: plain doogh
Table 2 Comparison of the initial and final values of the variables under study in the two groups
Group PYD FYD
Variable Before After P
i Before After P
i P
ii P
iii
Weight 78.1 ± 13.0 78.8 ± 13.2 0.058 77.6 ± 13.1 77.0 ± 12.8 0.003 0.83 0.49
Waist (cm) 101.34 ± 9.1 102.5 ± 9.2 0.035 98.25 ± 9.2 97.5 ± 8.8 0.013 0.090 0.007
BMI (kg/m
2) 30.0 ± 4.2 30.2 ± 4.3 0.079 28.6 ± 4.0 28.4 ± 4.0 0.005 0.09 0.03
Fat mass (%) 38.6 ± 9.6 39.8 ± 9.5 0.019 36.2 ± 8.8 34.7 ± 9.4 0.22 0.22 0.01
SBP (mm Hg) 128.2 ± 16.6 125.7 ± 6.9 0.22 125.7 ± 14.4 118.5 ± 21.0 0.007 0.42 0.056
DBP (mm Hg) 77.8 ± 10.8 77.0 ± 9.3 0.62 78.5 ± 10.3 73.4 ± 8.5 0.002 0.42 0.02
FSG (mmol/L) 9.6 ± 2.6 10.0 ± 3.2 0.32 10.5 ± 3.1 9.0 ± 2.8 0.001 0.13 0.10
Insulin(pmol/L) 177.8 ± 80.6 204.2 ± 90.3 0.01 141.0 ± 113.2 111.0 ± 82.0 0.002 0.06 0.001
HbA1c (%) 8.9 ± 1.6 8.5 ± 1.6 0.087 8.7 ± 1.8 7.8 ± 1.3 0.001 0.10 0.015
QUICKI 0.28 ± 0.02 0.27 ± 0.02 0.041 0.29 ± 0.02 0.30 ± 0.02 0.001 0.03 0.001
TG (mmol/L) 10.1 ± 4.8 10.1 ± 5.2 0.98 10.3 ± 5.3 8.6 ± 4.5 0.01 0.86 0.001
HDL-C (mmol/L) 2.5 ± 0.5 2.4 ± 0.5 0.52 2.6 ± .46 2.8 ± .42 0.043 0.15 0.001
TC (mmol/L) 10.1 ± 2.7 10.0 ± 3.0 0.68 10.3 ± 3.1 9.2 ± 1.8 0.001 0.68 0.10
LDL-C (mmol/L) 6.15 ± 1.8 6.1 ± 1.8 0.52 5.5 ± 1.7 5.0 ± 1.3 0.003 0.12 0.001
25(OH)D (nmol/L) 38.0 ± 22.8 33.4 ± 22.8 0.28 38.5 ± 20.2 72.0 ± 23.5 0.001 0.90 0.001
iPTH (ng/L) 55.0 ± 22.5 59.1 ± 18.2 0.28 52.5 ± 24.1 40.1 ± 15.6 0.001 0.12 0.001
ACR (mg/mmol) 41.8 ± 106.2 44.1 ± 158.2 0.88 36.2 ± 99.4 31.6 ± 68.9 0.61 0.74 0.40
Endothelin (μg/L) 0.80 ± 0.40 0.88 ± 0.41 0.67 0.9 5 ± 0.38 0.75 ± 0.64 0.001 0.50 0.06
E-selectin (μg/L) 16.1 ± 6.5 17.1 ± 6.9 0.42 18.1 ± 7.1 14.4 ± 5.7 0.001 0.14 0.035
MMP-9 (μg/L) 9.2 ± 5.3 9.6 ± 4.7 0.66 10.6 ± 4.2 8.3 ± 3.7 0.001 0.15 0.12
Data presented as mean ± standard deviation or percentage unless stated otherwise.
P
i: within group difference; P
ii: between-group at the baseline; P
iii: between group after the intervention
FYD: vitamin D-fortified doogh; PYD: plain doogh
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re-examined using ANCOVA with both FM and WC
together as confounders. The differences in FSG, serum
insulin and QUICKI still remained significant (P =
0.004, P <0 . 0 0 1a n dP < 0.001, respectively). Though
HbA1c significantly decreased in the FYD group,
between-group changes were not significant (P =0 . 1 0 0 )
(Table 3).
None of the components of the serum lipid profile dif-
fered significantly between the groups at baseline. By the
end of the intervention, TC, HDL-C and LDL-C did not
change in the PYD group but in the FYD group, TC
and LDL-C decreased and HDL-C increased significantly
(for all P < 0.001) (Table 2). Changes in serum concen-
trations of TC (P = 0.009), TG (P = 0.01), HDL-C (P =
0.044) and LDL-C- (P = 0.02) differed significantly
between the two groups (Table 3). To evaluate the
possible effect of ameliorated insulin resistance on lipid
profile, the differences were re-compared using
ANCOVA with QUICKI as a confounder. In this case,
all of these differences disappeared (TC P = 0.093; TG P
= 0.146; HDL-C P = 0.335; and LDL-C P = 0.194).
Biomarkers of endothelial function and urinary albumin
to creatinine ratio
Neither endothelial biomarkers nor ACR differed signifi-
cantly between the two groups at baseline. At the end of
the intervention period, however, in the PYD group the
changes in these variables were not statistically signifi-
cant but in the FYD group serum concentrations of
endothelin-1, E-selectin and MMP-9 all decreased signif-
icantly (Table 2) and between-group differences in their
changes were also significant (Table 3). To determine
the dependency of changes in the endothelial
Table 3 Comparison of changes in biomarkers during treatment with FYD or PYD
Change in FYD group
(n = 50)
Change in PYD group (n = 50) P
a
Waist (cm) -0.75 ± 2.8 +1.1 ± 3.6 0.005
BMI (kg/m
2) -0.17 ± 1.4 +0.25 ± 0.9 0.07
Fat mass (%) +1.1 ± 3.0 -1.0 ± 5.3 0.23
Systolic BP (mm Hg) -7.3 ± 18.5 -2.5 ± 14.6 0.15
Diastolic BP (mm Hg) -3.5 ± 7.8 -0.63 ± 9.3 0.09
FSG (mg/dL) -26.6 ± 45.6 +6.2 ± 44.8 < 0.0001
Fasting serum insulin (mU/L) -4.3 ± 9.6 +3.8 ± 10.3 < 0.0001
HbA1c (%) -0.9 ± 1.4 -0.4 ± 1.7 0.10
Quiccki index +0.01 ± 0.02 -0.005 ± 0.02 < 0.0001
TG (mg/dL) -30.3 ± 81.3 +0.12 ± 36.8 0.01
HDL-C (mg/dL) +2.4 ± 8.3 -0.6 ± 6.7 0.04
TC (mg/dL) -19.4 ± 34.8 -1.8 ± 31.7 0.009
LDL-C (mg/dL) -10.7 ± 24.2 -1.5 ± 16.9 0.02
25(OH)D (nmol/L) +32.6 ± 18.3 -2.7 ± 16.6 < 0.0001
iPTH (pg/ml) -11.7 ± 20.6 4.3 ± 58.3 0.07
Microalbumin (mg/dl) -6.3 ± 51.6 0.89 ± 24.8 0.38
Endothelin (ng/mL) 0.03 ± 0.55 0.35 ± 0.63 0.028
E-selectin (ng/mL) -3.8 ± 7.3 +0.95 ± 8.3 0.003
MMP-9 (ng/mL) -2.3 ± 3.7 +0.44 ± 7.1 0.02
Data are presented as ± standard deviation
aDifferences assessed by Student’s t-test
FYD, fortified yogurt drink; PYD, plain yogurt drink; BMI indicates body mass index; BP, blood pressure; FSG, fasting serum glucose; HbA1c, glycated hemoglobin;
TG, triglyceride; HDL-c high density lipoprotein; TC, total cholesterol; LDL-C, low density cholesterol; 25-OHD,25-hydroxyvitamin D; iPTH, intact parathyroid
hormone; MMP-9, matrix metalloproteinase 9.
Table 4 Comparison of the vitamin D status between PYD and FYD groups.
Deficiency n (%) Insufficiency n (%) Sufficiency n (%)
Before After Before After Before After
PYD 16(31.4) 21(48.8) 22(43.1) 14(32.6) 13(25.5) 8(18.6)
FYD 13(26.5) 2(4.5) 25(51) 5(4.4) 11(22.4) 37(84.1)
Total 29 (28.2) 23 (22.3) 47 (45.6) 19 (18.4) 24 (23.3) 45 (43.7)
*Vitamin D status defined as: Deficiency < 27.5 nmol/L; insufficiency ≥27.5 nmol/L to < 50 nmol/L; and sufficient ≥50 nmol/L. FYD, vitamin D-fortified doogh;
PYD: plain dough.
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or distribution of body fat, or serum 25(OH)D, the dif-
ferences were re-evaluated using ANCOVA with
changes of either QUICKI, FM and WC or 25(OH)D as
confounders. The between-group differences in changes
of serum endothelin-1 and MMP-9 remained significant
even after controlling for changes of QUICKI, FM and
WC (P =0 . 0 0 9a n dP = 0.005, respectively) but disap-
peared after controlling for serum 25(OH)D (P = 0.066
and P = 0.277, respectively). On the contrary, the
between-group difference in changes of serum E-selectin
remained significant after controlling for 25(OH)D (P =
0.011) but disappeared after controlling for QUICKI,
FM and WC (P = 0.092). The between-group changes in
E-selectin (P = 0.026), endothelin-1 (P = 0.006) and
MMP-9 (P = 0.008) all remained significant when only
QUICKI changes were controlled as a confounder.
These changes, however, were not accompanied by a
significant decrease in urinary albumin excretion as
evaluated by ACR either within or between groups.
Discussion
The high occurrence of poor vitamin D status in our
subjects is comparable with other reports from Iran
[10,17]. While the occurrence of vitamin D deficiency
and insufficiency did not change after a 12-week inter-
vention period in the PYD group, a significant decrease
of poor vitamin D status in the FYD group indicated
both the high efficiency of the dosage used and the high
bioavailability of vitamin D3 in the Persian yogurt drink,
doogh. All participants completed the intervention per-
iod and the compliance of the patients was 100%, as
judged by checking the consumption tables, follow-up
calls, the subjects’ reports and, in the FYD group, the
expected rise in serum 25(OH)D. However, the persis-
tence of vitamin D deficiency in the FYD group (4.5%)
despite a daily intake of 1000 IU vitamin D for 12 weeks
can be a subject of considerable argument. Interestingly,
those subjects in the FYD group whose vitamin D status
remained undesirable after the intervention did not
show any appreciable changes in their glycemic and
endothelial biomarkers. A similar observation has
already been reported [18]. Considering the high preva-
lence of vitamin D deficiency in Iranian subjects either
with or without diabetes [17,19] and assuming the same
prevalence of “non-responders” among the whole popu-
lation, a huge number of people may not benefit from
intake of the usually recommended amount of vitamin
D. This individual variability may be, at least in part,
explained by vitamin D receptor (VDR) polymorphisms.
A significant association between VDR variants and sus-
ceptibility to several diseases including cancer [20,21],
ulcerative colitis [22], metabolic syndrome [23] and both
types of diabetes [24,25] has already been reported. The
upcoming results from our study group will soon
address the role of VDR genotypes on the variation of
outcomes after improvement of vitamin D status in sub-
jects with T2D [12].
Significant reductions in BMI, WC and FM following
12 weeks of daily intake of 1000 IU vitamin D via a for-
tified-doogh, are consistent with our previous report
[10]. An inverse association between vitamin D status
and adiposity shown in older people [26] was further
c o n f i r m e di nb o t hc h i l d r e n[ 2 7 , 2 8 ]a n da d u l t s[ 2 9 ] .
From a mechanistic point of view, intracellular calcitriol
has been implicated in both enhancing and inhibiting
adipogenesis in cell culture [30] probably through per-
oxisome proliferator-activated receptor-gamma (PPAR-
g) and retinoid × receptor (RXR)-involved pathways [31].
However, some studies have failed to show any addi-
tional effect of vitamin D and calcium supplementation
during weight loss on body adiposity [32] and in obese
children, poor vitamin D status has been suggested as
the consequence, rather than the cause, of adiposity
[33]. Notwithstanding, in that study obese subjects con-
sumed only 0.25 μg (10 IU)/day of vitamin D [32], a
dosage far less than the amount considered sufficient to
optimize circulating 25(OH)D [34]. Moreover, weight
reduction may mask the possible influence of vitamin D
on adipogenesis. To overcome these problems, both an
efficient dosage of vitamin D and a weight maintenance
intervention were used in the present study.
Poor vitamin D status has been recognized as an inde-
pendent risk factor for incident arterial hypertension
and it is believed that vitamin D supplementation can
reduce SBP by 2 to 6 mmHg [35]. However, in this
study despite the high occurrence of poor vitamin D sta-
tus among the participants, no significant effect of regu-
lar vitamin D intake on blood pressure (either SBP or
DBP) was observed. It should be noted that most of our
subjects were normotensive as the blood pressure of
only eight (15.4%) and nine (17.6%) subjects in the FYD
and PYD groups, respectively, was above 135/85 mmHg.
Even re-analysis in the subgroups with above normal BP
did not show any significant change. The possible effect
of vitamin D on BP merits further research.
Amelioration of the glycemic status of our subjects
after a 12-week intervention period further confirms our
previous observations [10]. Attenuation, but still persis-
tence, of significant differences after controlling for WC
and FM might imply both direct (improvement of insu-
lin secretion and insulin sensitivity) and indirect (decre-
ment of FM and weight) effects of cholecalciferol on
glycemic status.
Contrary to a previous report [10], a significant
improvement in lipid profile was observed in the FYD
group. However, the disappearance of significant
between-group changes after controlling for QUICKI
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may be secondary to its ameliorating effect on glycemic
status. Unlike our finding, in a 2-year RCT involving
167 men aged 50 years and older, daily intake of 400
mL low-fat milk fortified with 1,000 mg calcium and
800 IU vitamin D3 did not affect blood lipids [36]. In
contrast, daily intake of 1,200 mg calcium and only 400
IU vitamin D in overweight/obese women during a 15-
week weight reduction intervention resulted in lower
serum LDL-C, compared to those who just had a weight
reducing diet [37]. Some of these discrepancies may
relate to the baseline blood lipids and 25(OH)D of the
subjects. It is noteworthy that our subjects in the pre-
sent study, compared to the previous one, had lower
lipidemic status (especially higher for both TG and TC)
so that they might be more responsive to a nutritional
intervention. The effect of vitamin D on blood lipids
and lipoproteins needs to be elucidated by further pre-
cisely controlled clinical trials.
Elevated circulating concentrations of endothelin and
E-selectin have been attributed to the boosted produc-
tion of vasoconstrictors and increased adhesion of and
permeability to leukocytes, respectively [38]. On the
other hand, a high glucose milieu has been shown to
induce over-expression of several matrix metalloprotei-
nases, notably MMP-9, thus promoting matrix degrada-
tion, atherogenesis and plaque instability [39]. It has
been recently demonstrated that down-regulation of
MMP-9 via insulin treatment will result in reduction of
intimal lesions in atherosclerosis-prone diabetic apoE
(-/-) mice [40]. In the current study, endothelial status,
as evaluated by serum concentrations of E-selectin,
endothelin-1 and a vascular inflammation marker,
MMP-9, were improved after daily intake of 1,000 IU
vitamin D via fortified-doogh consumption. This was
not, however, accompanied by a significant change in
urinary excretion of albumin. Soluble E-selectin together
with a coagulation factor, XIIa, has been associated with
ten-year macrovascular events in subjects with T2D
[41]. Poor vitamin D status-related endothelial dysfunc-
tion in diabetes may be partly mediated by nuclear fac-
tor -B (NF-B)-linked inflammation [42] and
endothelial progenitor cell depletion [43]. Persistence of
a significant between-group difference of serum
endothelin-1 and MMP-9, but not E-selectin, after con-
trolling for QUICKI, FM and WC implies a direct effect
of vitamin D3 on the first two endothelial biomarkers
but an indirect effect on E-selectin. It has recently been
reported that dyslipidemia and high BMI are related to
macroangiopathy while the duration of disease and high
HbA1c are associated with microangiopathy [44]. Vita-
min D replenishment may, therefore, be considered as
an effective preventive measure against development of
both macro- and micro-angiopathy by improving lipid
profile, BMI and HbA1c. This effect may be comparable
with that of the combination of metformin and atrovas-
tatin [45].
Several observational studies have suggested an asso-
ciation between vitamin D deficiency and vascular dis-
ease but only a handful of them have examined the
effect of vitamin D on endothelial function. In a small
pilot study on 34 T2D subjects with vitamin D insuffi-
ciency (25OHD < 50 nmol/L), a single, mega dose of
vitamin D2 (100,000 IU) resulted in a significant
improvement of endothelial function [46]. Monthly
intramuscular injection of 300,000 IU vitamin D to sub-
jects with subclinical vitamin D deficiency for 3 months
had a favorable effect on endothelial function, as evalu-
ated by brachial artery flow-mediated dilatation (FMD)
[9]. In a cross-sectional study, circulating 25(OH)D
inversely correlated with MMP-9 and vitamin D status
was found to be the only predictor of MMP-9. Follow-
ing 1-year supplementation of just vitamin D deficient
subjects (n = 41), a significant reduction in MMP-9
(-68%) was observed [47]. Our finding of the suppressive
effect of vitamin D on serum MMP-9 in subjects with
T2D further supports previous reports. Notwithstanding,
all these trials have been conducted on rather small
sample sizes and in widely disparate settings with differ-
ent adducts and doses of vitamin D and outcome mea-
sures resulting in poor comparability.
In the current study, a significant decrease in serum
concentrations of endothelin-1, E-selectin and MMP-9
even after controlling for QUICKI implies the direct
effect of vitamin D independent of glycemic status. In
accord with this notion, a recent study demonstrated
that decreased vascular endothelial cell expression of
VDR and 1-a-hydroxylase due to vitamin D deficiency
is associated with vascular endothelial dysfunction [48].
However, the limitations o ft h i ss t u d ym u s tb et a k e n
into consideration. Since the study was conducted dur-
ing the cold seasons, the vitamin D status of our sub-
jects does not reflect its status during the entire year.
Moreover, the changes observed after a 12-week inter-
vention cannot necessarily be extrapolated to the long-
term effects.
Conclusions
In conclusion, the present study showed that glycemic
status, lipid profile and biomarkers of endothelial func-
tions were all improved following regular vitamin D
intake in subjects with T2D but microalbuminuria was
not affected significantly. A remarkable rise in circulat-
ing 25(OH)D3 following regular intake of fortified
doogh indicated the high bioavailability of vitamin D in
this Persian yogurt drink. This can be considered by
health stakeholders for further fortification programs.
Clearly, future randomized and controlled studies with a
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Page 8 of 10longer duration and follow up of clinical outcomes are
needed to confirm the potentially beneficial effect of
vitamin D repletion in patients with T2D.
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